Trial Halted for Bleeding Reduction With Abelacimab in AF

The phase 2 AZALEA-TIMI 71 trial in AF shows "an overwhelming reduction" in major and clinically relevant nonmajor bleeding with investigational Factor XI inhibitor abelacimab vs rivaroxaban.

Related Keywords

United States ,America ,Dan Bloomfield ,Marc Sabatine ,National Blood Clot Alliance ,Drug Administration ,Anthos Therapeutics ,Thenew England Journal ,North America ,Latin America ,Middle East ,Leslie Lake ,Atrial Fibrillation ,F Atrial Fibrillation ,Thromboembolism ,Anticoagulation Therapy ,Anticoagulant ,Anticoagulation ,Hemorrhage ,Bleeding ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Accident ,Embolism ,Venous Thromboembolism ,Thrombus ,Blood ,Europe ,European ,Factor Xi Deficiency ,Aemophilia C ,Lasma Thromboplastin Antecedent Pta Deficiency ,Rosenthal Syndrome ,Genetics ,